No headlines found.
PRNewswire (Thu, 29-Feb 7:00 AM ET)
The Fund seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index (ticker symbol PMBI) (the "Underlying Index"). The ALPS Medical Breakthroughs ETF invests in the public equity markets of the United States and in the stocks of companies operating in the biotechnology sectors. The fund invests in stocks of mid cap and small cap companies with a market capitalization of no less than $200 million and no more than $5 billion. It seeks to replicate the performance of the S-Network Medical Breakthroughs Index, by investing in the stocks of companies as per their weightings in the index.
Alps Medical Breakthroughs ETF trades on the ARCA stock market under the symbol SBIO.
As of March 28, 2024, SBIO stock price climbed to $35.75 with 9,532 million shares trading.
SBIO has a market cap of $115.29 million. This is considered a Micro Cap stock.
In the last 3 years, SBIO stock traded as high as $51.25 and as low as $23.21.
SBIO has underperformed the market in the last year with a price return of +33.3% while the SPY ETF gained +33.6%. SBIO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +6.7% and -0.6%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
SBIO support price is $34.92 and resistance is $36.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SBIO stock will trade within this expected range on the day.